Table 1

Distribution of HLA-B*51 and HLA-B*52 allele groups in healthy controls and Takayasu's arteritis patientsa

Characteristics

n

HLA-B*52+ (%)

P

OR (95% CI)

HLA-B*51+ (%)

P


HC

210

14 (6.7)

52 (24.8)

Men

97

6 (6.2)

23 (23.7)

Women

113

8 (7.1)

29 (25.7)

TAK

330

69 (20.9)

0.000

3.7 (2.02 to 6.77)

75 (22.7)

0.64

Men

42

7 (16.7)

0.063

12 (28.6)

0.53

Women

288

62 (21.5)

0.000

3.6 (1.66 to 7.79)

63 (21.9)

0.43

Age at onset

< 40 years

240

58 (24.2)

0.024

0.43 (0.20 to 0.91)

49 (20.4)

0.11

≤ 40 years

75

9 (12.0)

22 (29.3)

Angiographic subtypeb

Type I

130

17 (13.1)

0.005

0.43 (0.23 to 0.78)

28 (21.5)

0.78

Type Iia

21

8 (38.1)

6 (28.6)

Type Iib

9

3 (33.3)

2 (22.2)

Type III

13

5 (38.5)

3 (23.1)

Type IV

15

3 (20.0)

1 (6.7)

Type V

142

34 (23.9)

35 (24.6)

Surgery (all)

Present

66

9 (13.6)

0.092

0.51 (0.24 to 1.09)

13 (19.7)

0.62

Not present

246

58 (23.6)

57 (23.2)

Surgery after IS treatment

Present

36

7 (19.4)

1.0

9 (25)

0.67

Not present

273

59 (21.6)

60 (22.0)

Refractory disease

Refractory

114

31 (27.4)

0.084

1.68 (0.97 to 2.93)

20 (17.5)

0.12

Not refractory

193

35 (18.1)

49 (25.4)


aHC, healthy control; IS, immunosuppressive; TAK, Takayasu's arteritis. Subgroup analysis was performed between groups with or without known clinical features. bP vs other all other subtypes.

Sahin et al. Arthritis Research & Therapy 2012 14:R27   doi:10.1186/ar3730

Open Data